ESTRO and EORTC announce new collaboration


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) have joined forces to launch a new initiative, E2-RADIatE (EORTC-ESTRO Radiation Infrastructure for Europe), which aims to expand the evidence base for radiation oncology.

The initiative, which was launched at the ESTRO 37 conference in Spain last weekend, intends to put in place a pan-European infrastructure to encourage research collaboration that will also involve other oncology disciplines.

E2-RADIatE will commence activity with two projects. OligoCare will collect evidence for best practice in the treatment of oligometastases. A proton therapy project will provide an effective data-sharing platform for proton therapy outcomes and aims to recruit all patients treated in proton therapy centres throughout Europe. The project is expected to be up and running within a year, with approximately 2,000 patients recruited in five years.

“We believe that, through E2-RADIatE, we will be able to improve the efficiency of research projects, both in their take-up and conduct, and offer effective pan-European models to research partners,” said EORTC President, Professor Bertrand Tombal, Chairman of the Division of Urology and Professor of Urology at the Université Catholique de Louvain (UCL), Cliniques Universitaires Saint-Luc, Brussels, Belgium.